论文部分内容阅读
目的探讨干扰素β1b(IFN-β1b)在复发-缓解型多发性硬化(RRMS)中的疗效与外周血中Th17细胞的关系。方法收集11例RRMS患者,给予6个月IFN-β-1b治疗。评估治疗前后扩展残疾状态评分(EDSS)及核磁共振(MRI)T2病灶数的变化。并通过流式细胞术检测治疗前患者外周血单个核细胞(PBMC)中Th17细胞的数量。结果 11例RRMS患者根据EDSS评分的变化分为治疗有效组和无效组。两组之间EDSS评分及MRI T2病灶数在治疗前无统计学差异(P>0.05),治疗后有效组EDSS评分和MRI T2病灶数较无效组明显减少(P<0.05)。治疗前PBMC中Th17细胞数量在无效组较有效组明显增加(P<0.05)。结论 IFN-β-1b治疗对Th17细胞介导的RRMS无明显疗效。
Objective To investigate the relationship between the efficacy of interferon β1b (IFN-β1b) and Th17 cells in patients with relapsing-remitting multiple sclerosis (RRMS). Methods Eleven patients with RRMS were collected and treated with IFN-β-1b for 6 months. The changes of EDSS and T2 lesions before and after treatment were evaluated. The number of Th17 cells in peripheral blood mononuclear cells (PBMC) of patients before treatment was detected by flow cytometry. Results 11 cases of RRMS patients were divided into treatment-effective group and ineffective group according to the change of EDSS score. There was no significant difference in EDSS score and MRI T2 lesion number between the two groups before treatment (P> 0.05). EDSS score and MRI T2 lesion count of the effective group were significantly lower than those of the ineffective group after treatment (P <0.05). Before treatment, the number of Th17 cells in PBMC in the invalid group was significantly higher than that in the effective group (P <0.05). Conclusion IFN-β-1b treatment has no significant effect on Th17 cell-mediated RRMS.